ISLAMABAD  - The single dose locally finished and packed corona vaccine ‘PakVac’ has qualified the painstaking quality assurance (QA) test at the National Institute of Health (NIH) and reflected its effectiveness. 

The scientists at NIH observing the research on local anti-COVID-19 vaccine informed The Nation that the China based CanSino bio vaccine was brought at NIH in concentrates in powder form. 

The researchers said that the vaccine in powder form was further diluted at NIH and then its quality control testing was done. 

According to the NIH scientists, in the next step its quality assurance was done covering the target gene, vector testing and examination of protein excretion. “The target gene injected in the body gives a call to the immunity system to develop antibodies,” said a senior scientist at NIH. He said that this target gene is carried in a vector which works like an envelope and protein excretion takes place in it. 

He said that the PakVac has qualified that the QA test and after that its report is sent to the Drugs Regulatory Authority of Pakistan (DRAP) to test the sterility that the vaccination does not carry any contamination. 

The NIH official said that like CanSino Bio, the PakVac is also a single shot COVID-19 vaccine and the government will likely give its final approval which is expected in a week. Executive Director (ED) NIH Maj. Gen Aamer Ikram when contacted for comments said that all details regarding the vaccine will be released next week.